Samuel Wallis

Head of Case Management, Patient Safety, Bristol Myers Squibb

Sam heads Case Management in Worldwide Patient Safety at Bristol Myers Squibb, based in London. He joined BMS through its acquisition of Celgene and led the integration of the two companies' case processing, including moving the BMS safety database to the cloud. He speaks widely on case intake innovation and AI adoption in pharmacovigilance.

Events Samuel Wallis has spoken at

Pharmacovigilance Europe Congress 2027 19 May 2027 – 20 May 2027